Tumor News and Research

RSS

Magnetic nanoparticles for ovarian cancer treatment

A paper published in the January issue of the journal Nanomedicine could provide the foundation for a new ovarian cancer treatment option - one that would use an outside-the-body filtration device to remove a large portion of the free-floating cancer cells that often create secondary tumors.

28 Jan 2011

Crossed eyes in adults can also be corrected

Since she was a baby, Carleen Trautz's left eye turned outward, rather than looking straight ahead, and it made her life miserable.

28 Jan 2011

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer.

27 Jan 2011

TD2 and Flagship Biosciences offer combined oncology and pathology services

TGen Drug Development (TD2) and Flagship Biosciences today announced a strategic alliance that should help speed new drugs safely into human testing and quickly benefit cancer patients.

27 Jan 2011

Fibroblasts help 'recruit' immune cells for tumor growth

The most common connective tissue cell in animals is the fibroblast, which plays an important role in healing wounds. But Dr. Neta Erez of Tel Aviv University's Sackler Faculty of Medicine has now demonstrated that fibroblasts can also do a body great harm, helping to "recruit" immune cells for tumor growth.

27 Jan 2011

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Cancer researchers at Princess Margaret Hospital (PMH) have discovered that targeting an enzyme called Uroporphyrinogen Decarboxylase (UROD) can sensitize diseased tissue to radiation and chemotherapy, which could mean fewer side effects for individuals with head and neck cancer.

27 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II brain cancer clinical trial

Cutting edge, patient-specific vaccine treatments like DCVax® provide for a longer life expectancy along with a better quality of life for brain cancer patients, an improvement over current conventional brain tumor treatments. "The vaccine that I received has extended the median survival of Grade IV brain cancer (GBM) from 14.6 months, with conventional treatment, to over 36 months," stated Bob Gibbs, a 7 year brain cancer survivor, who has defied the odds statistically, thanks to the experimental brain cancer vaccine DCVax®.

25 Jan 2011

Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Colon Cancer test

Genomic Health, Inc. today announced presentation of three studies at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, including one finding that high tumor grade was not a marker of higher recurrence risk in stage II colon cancer, suggesting that other markers, such as the Oncotype DX® Recurrence Score® (RS) test as well as T-stage and mismatch repair (MMR) status, should be considered by physicians during the treatment decision-making process.

25 Jan 2011

Taiwanese research team develops large-scale proactive cancer treatment system first-generation prototype

A Taiwanese research team, led by Prof. Ming-Shing Young of Department of Electrical Engineering at National Cheng Kung University (NCKU), has successfully developed a large-scale proactive cancer treatment system first-generation prototype which includes Frequency-Adjustable High Frequency Induction Heating Machine (HFIHM) and 3D Magnetically Guiding Endoscope System (3DMGES).

25 Jan 2011

Study results of Pathwork Diagnostics's Tissue of Origin Test presented at ASCO 2011

Pathwork Diagnostics, Inc., a privately held molecular diagnostics company focused on oncology, announced today that results from a decision impact study of its Tissue of Origin Test were presented this weekend at the ASCO 2011 Gastrointestinal Cancers Symposium in San Francisco.

25 Jan 2011

Sanofi-aventis acquires world-wide license for ADC products

Oxford BioTherapeutics today announces that sanofi-aventis has acquired an exclusive world-wide license to one of OBT's internal preclinical antibody programs.

25 Jan 2011

PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011

PharmaEngine, Inc. announced today that two phase II studies of PEP02 (liposome irinotecan) in gastric and pancreatic cancer studies were presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco, CA, USA.

25 Jan 2011

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Glioblastoma, the most common and lethal form of brain cancer and the disease that killed Massachusetts Senator Ted Kennedy, resists nearly all treatment efforts, even when attacked simultaneously on several fronts. One explanation can be found in the tumor cells' unexpected flexibility, discovered researchers at the Salk Institute for Biological Studies.

25 Jan 2011

Researchers design engineered organ study the use of nanoparticles in breast cancer detection

Purdue University researchers have reproduced portions of the female breast in a tiny slide-sized model dubbed "breast on-a-chip" that will be used to test nanomedical approaches for the detection and treatment of breast cancer.

25 Jan 2011

New study shows biomarker test can aid in early, precise diagnosis of melanoma

A new study shows that a test of biomarkers for DNA methylation is technically feasible and could aid in earlier, more precise diagnosis of melanoma.

24 Jan 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.

24 Jan 2011

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus Inc. today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus' proprietary cancer vaccine technology.

24 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Northwest Biotherapeutics announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax for Glioblastoma multiforme brain cancer.

24 Jan 2011

CRI, Oncovir sign new investment agreement to produce immunological stimulant

Cancer Research Institute, a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund, a joint initiative with the Ludwig Institute for Cancer Research, has completed a new investment agreement with Oncovir, a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol- (Poly-ICLC).

24 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Tumor News and Research

Magnetic nanoparticles for ovarian cancer treatment

Crossed eyes in adults can also be corrected

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

TD2 and Flagship Biosciences offer combined oncology and pathology services

Fibroblasts help 'recruit' immune cells for tumor growth

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Northwest Biotherapeutics resumes enrollment in DCVax Phase II brain cancer clinical trial

Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Colon Cancer test

Taiwanese research team develops large-scale proactive cancer treatment system first-generation prototype

Study results of Pathwork Diagnostics's Tissue of Origin Test presented at ASCO 2011

Sanofi-aventis acquires world-wide license for ADC products

PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Researchers design engineered organ study the use of nanoparticles in breast cancer detection

New study shows biomarker test can aid in early, precise diagnosis of melanoma

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

CRI, Oncovir sign new investment agreement to produce immunological stimulant

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News